Denali Therapeutics Inc (NAS:DNLI)
$ 20.61 -0.71 (-3.33%) Market Cap: 2.97 Bil Enterprise Value: 2.28 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 57/100

Denali Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript

Sep 11, 2019 / 03:40PM GMT
Release Date Price: $19.64 (+3.86%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

So great. So thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Pleased to have Denali with us.

Just quickly before we get going, I need to read an important disclosure statement. Please note that all important disclosures including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. Or you can pick up your very own copy at the registration desk.

Questions & Answers

Matthew Kelsey Harrison;Alexander O. Schuth<
Morgan Stanley, Research Division - Executive Director

So I'm very pleased to have Alex Schuth with us. And Alex, I thought -- look, to start off, there've been a handful of neurology neurodegeneration companies that have come to market in the last 2 or 3 years. I thought maybe just it would be helpful to highlight what's your approach and why you think that approach is unique?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot